Biographies des conférenciers

BIOGRAPHIES DES CONFÉRENCIERS 

FACULTY BIOS



Abele, Jonathan

Dr. Jonathan Abele is an Associate Professor in the Department of Radiology and Diagnostic Imaging at the University of Alberta in Edmonton. He has an active clinical practice in Nuclear Medicine, SPECT/CT, PET/CT, general Radiology and body CT Imaging and is a partner in Medical Imaging Consultants – a group of over 80 Radiologist and Nuclear Medicine physician partners. He is a member of the Residency Program Committee for Nuclear Medicine at the U of A. This program currently has 13 active Nuclear Medicine residents.

Arsenault, Frédéric

Dr Frédéric Arsenault est un nucléiste gradué de l’Université de Montréal en 2016. Il a complété sa formation par une année supplémentaire en oncologie nucléaire dans la pittoresque ville de Québec sous la supervision des Dr Buteau, Beauregard et Beaulieu. La majeure partie de son temps fut consacrée au traitement des patients atteints de tumeurs neuroendocrines par la thérapie aux radioligands, ou PRRT. Depuis le 1er juillet 2018, il est de retour à temps plein comme nucléiste au Centre Hospitalier de l’Université de Montréal.

Beaulieu, Alexis

Le Docteur Alexis Beaulieu a gradué au programme de médecine nucléaire de l’Université de Montréal en 2015, suite à quoi il s’est joint à l’équipe du CHU de Québec – Université Laval, au sein de l’équipe pré-existante de Radiothérapie personnalisée aux récepteurs peptidiques (Personalized Peptide Receptor Radiation Therapy – P-PRRT).

Il a par la suite complété une formation complémentaire – ou Fellowship – en PRRT, mais également en Radio-Ligand Therapy (RLT) au sein de l’équipe de médecine nucléaire et de Theragnostics du Prof. Rodney J. Hick en 2017-2018.

Ses intérêts et ambitions actuels incluent le développement et l’expansion des programmes de thérapie ciblées en médecine nucléaire, avec un intérêt particulier pour le cancer de la prostate.

Beauregard, Jean-Mathieu

Dr. Jean-Mathieu Beauregard, MD, MSc, FRCPC, is Assistant Professor of Nuclear Medicine at Université Laval and Clinician-Scientist at CHU de Québec - Université Laval in Quebec City, Canada. He is a Nuclear Medicine Physician cumulating over 11 years of experience in molecular imaging and PRRT of neuroendocrine tumours. Following his fellowship at the Peter MacCallum Cancer Centre (Melbourne, Australia), he started a PRRT program in Quebec City and, more recently, launched a first-of-its-kind prospective clinical trial of personalized Lu-177-octreotate PRRT. Dr. Beauregard also conducts a pre-clinical research program in which he investigates the application of novel radiosensitizing approaches for radionuclide therapy.

Bénard, François

To come / À venir

Bennett, Paige

Paige Bennett, MD, ABNM is a Professor of Nuclear Medicine of Nuclear Medicine at Wake Forest University Health Sciences in Winston-Salem, North Carolina. In addition to her academic practice of clinical Nuclear Medicine/PET and Theranostics, she edited and authored Diagnostic Imaging: Nuclear Medicine and Specialty Imaging: PET (Amirsys/Elsevier, Inc.). Her @nuclear_radiology page on social media site Instagram is at the forefront of global nuclear medicine education in the free and open access to medical education movement (#FOAMed and #FOAMrad). She currently serves as Chair of the Women in Nuclear Medicine committee for the Society of Nuclear Medicine and Molecular Imaging. She attended University of Virginia School of Medicine, Wake Forest University Health Sciences for her Nuclear Medicine residency, and is currently obtaining a Master of Education in the Health Professions through Johns Hopkins University.

Boivin, Jonathan

Jonathan Boivin a gradué en génie physique à l'Université Laval, puis a complété une maîtrise en génie biomédical à l'Université de Montréal. Il a récemment terminé un doctorat en physique à l'Université Laval et travaille maintenant à Québec comme physicien médical clinique au service de radio-oncologie du CHU de Québec - Université Laval. Il vient également de compléter un programme de résidence en physique de la radio-oncologie dirigé par l'Université McGill. Au cours de ses études, il a mené plusieurs recherches sur le développement d'instruments de mesure de dose de rayons X au CT et en radiologie interventionnelle. Il participe désormais au déploiement d'un programme de contrôle qualité et d'optimisation des protocoles CT en imagerie médicale au sein du CHU de Québec - Université Laval.

Brown, Shannon

To come / À venir

Brunken, Richard

Richard C. Brunken MD is the Director of Nuclear Cardiology in the Department of Nuclear Medicine at the Cleveland Clinic, and is a Clinical Professor (Department of Radiology) in the Cleveland Clinic Lerner College of Medicine of Case Western University.  He is Board Certified in Internal Medicine, Cardiology and Nuclear Medicine, and serves on the Editorial Boards of the Journal of Nuclear Medicine and the Journal of Nuclear Cardiology.

Buteau, Jean-François

Graduated from Montreal University in 2011, he underwent a radioisotope therapy fellowship with Dr. Sandy McEwan at the Cross Cancer Institute in Edmonton, Alberta from 2011 to 2012. He then joined Dr. McEwan’s therapy program as a staff for one more year. He later moved back to Québec City, where he helped ramp up the NET and Diagnosis Nuclear Medical Program.

Chan, Denise

Denise Chan was born and raised in Vancouver, British Columbia where she obtained her Medical Degree from the University of British Columbia. She completed her Diagnostic Radiology and Nuclear Medicine Residency training in London, Ontario at the University of Western Ontario. She is currently a partner with EFW Radiology in Calgary, the co-lead of the Nuclear Medicine Division in the South Health Campus Hospital and a Clinical Assistant Professor at the University of Calgary. She is currently an Examiner for the Royal College of Nuclear Medicine and a Board Member at the CANM.

Dalipaj, Mary

Mary Dalipaj is a proud Nuclear Medicine Technologist who spent most of her career at the University of Ottawa Heart Institute where she was the Director of Clinical Operations in integrated cardiac imaging modalities. Her current role is as a Medical Information and Application Specialist with the Pharmaceutical Diagnostics division of GE Healthcare.  She is based in Ottawa and covers North America. Published author, presenter and educator.

Dery-Jeamspm, Félix

To come / À venir

Deschamps, Xavier

Titulaire d’un baccalauréat en pharmacie de l’Université de Montréal et d’une maîtrise en pharmacie d’hôpital de l’Université Laval, Xavier Deschamps exerce la pharmacie à l’Hôtel-Dieu de Québec depuis 2005. Responsable du volet pharmacie du programme de nutrition parentérale à domicile depuis 2007, il a été quelques années chargé de cours pour la nutrition parentérale auprès des étudiants à la maîtrise en pharmacothérapie avancée de la Faculté de pharmacie de l’Université Laval. Il exerce par ailleurs principalement à la clinique pré-opératoire et à l’unité de chirurgie générale. Il est également en charge de la certification en manipulation stériles pour les produits non-dangereux des assistants-techniques en pharmacie et des pharmaciens de l’Hôtel-Dieu de Québec depuis 2012. En 2015, il s’est associé avec le service de médecine nucléaire pour la certification en manipulation stériles des technologues.

Doerr, Cynthia

Cynthia Doerr, MD, is the Director of Clinical Programs for Serene, LLC, a privately held company that develops and commercializes radiolabeled diagnostic and therapeutic products for rheumatologic, cardiovascular, and oncologic conditions in human and veterinary medicine using the isotope Sn-117m. She earned her MD at the University of Nebraska Medical Center, and completed a Fellowship in Pediatric Infectious Diseases at Baylor College of Medicine. She practiced Pediatric Infectious Diseases and Hospital Epidemiology for five years in San Antonio, Texas, and then worked in a global healthcare venture capital firm for 13 years before joining Serene in 2014.

Eddy, Katie

To come / À venir

Flood, Kathy

To come / À venir

Godoy, Tassia (Ribeiro Monteiro de)

Dr. Tássia Godoy MD is a Nuclear Medicine fellow at University of British Columbia affiliated Teaching Hospitals focusing on scintigraphy and PET-CT imaging, and also focusing on the expected opportunities for the development of new therapeutic agents using radioligand therapy. She completed her Nuclear Medicine training at São Paulo, Brazil, where she also completed a post-graduation in Dermatology and has worked at different private clinics and hospitals in both areas. On completion of her fellowship her aim is to go back to Brazil to work as a Nuclear Medicine specialist with emphasis in the theranostic field and in the hybrid imaging.
Guerin, Brigitte

Brigitte Guérin est titulaire de la chaire Jeanne-et-J.-Louis-Lévesque en radiobiologie à l'Université de Sherbrooke (UdeS). Professeure titulaire au Département de médecine nucléaire et de radiobiologie, elle est également chef du laboratoire de radiochimie au Centre d’imagerie moléculaire (CIMS) du CIUSSSE-CHUS. Après avoir reçu son doctorat en chimie organique de l’UdeS, elle a complété une formation postdoctorale sous la direction du professeur Yvan Guindon à l’Institut de recherche clinique de Montréal, où elle a continué à travailler comme chercheur sénior jusqu’en 2002 pour ensuite occuper le poste de directrice de la chimie médicinale chez IPS Pharma Inc. En 2007, elle a accepté un poste de professeur de l’UdeS où elle a rapidement établi un programme de recherche original grâce à son savoir-faire et à son expertise en radiochimie. Depuis, elle a établi des collaborations avec de nombreux groupes, obtenant d’importants financements tout en se forgeant une excellente réputation internationale dans le domaine de la synthèse de radiotraceurs à des fins d'imagerie moléculaire. Elle a publié plus de 81 articles scientifiques dans des revues à comité de lecture, a des brevets en instance, a avancé 13 radiotraceurs du laboratoire vers la clinique, et a donné 43 conférences comme chercheur invitée dans des congrès internationaux.

Brigitte Guérin holds the Jeanne-and-J.-Louis-Lévesque Chair in Radiobiology at Université de Sherbrooke (UdeS). Full Professor at the Department of Nuclear Medicine and Radiobiology, Dr Guérin is also Head of the Radiochemistry Laboratory at CIUSSSE-CHUS Molecular Imaging Centre (CIMS). After receiving her Ph.D. in organic chemistry from UdeS (1994), she completed a postdoctoral training under the supervision of Prof. Yvan Guindon at the Montréal Clinical Research Institute, staying on as Senior Research Associate until 2002 when she accepted a position as Director of Medicinal Chemistry at IPS Pharma Inc. In 2007, she accepted a tenure-track faculty position at the UdeS Department of Nuclear Medicine and Radiobiology. She rapidly established an original radiochemistry research program as an independent researcher, based on her extensive know-how and expertise in the field of radiochemistry. She has since established very productive research collaborations with numerous research groups, securing major research funding while forging an international reputation for excellence in syntheses of radiotracersfor the purposes of molecular imaging. She has published over 81 scientific articles in peer-reviewed journals, has patents pending, has advanced 13 radiotracers from the bench to clinical trial, has given 43 invited lectures at international scientific meetings, and has vulgarized her work for public media in both official languages.

Harvey, Gilles-Philippe

To come / À venir

Hatazawa, Jun

To come / À venir

He, Wei

To come / À venir

Kairemo, Kalevi

Prof Kairemo graduated with a MSc(Eng) degree from the Department of Chemical Engineering at Helsinki University of Technology in 1980 before undertaking medical training (MD, PhD) at the University of Helsinki, Finland. He undertook specialist training in Clinical Chemistry, Nuclear Medicine, Health Care Administration and Clinical Pharmacology at Helsinki University (Central Hospital) and then had a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center from 1989-91 and 1993 in New York. 

Prof Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). Since 2009, he has been Chief of Nuclear Medicine and Molecular Radiotherapy (Theragnostics) at the Docrates Cancer Center, in Helsinki.  Since 2015 he has acted as Visiting Professor in the Nuclear Medicine Department of The University of Texas MD Anderson Cancer Center.

Prof Kairemo has also held posts in industry, as Medical Director of CTT Cancer Targeting Technologies (2001-6), Medical Director of Imanext Ltd (2006-8) and Clinical Director at Advanced Accelerator Applications SA, a joint French-Italian initiative.

Prof Kairemo has wide experience in the development of tumor-seeking compounds, including monoclonal antibodies, specific phage-display peptides and cytotoxic drugs, and he has coordinated several EU Research Program proposals, including as the National Coordinator and Management Committee Member for the European Union COST Action Project (BM 0607, Targeted Radionuclide Therapy) from 2007-11. He has been developing intelligent targeting nanoparticles which contained cytotoxic compounds or tracers (also for MRI, optical  or ultrasound imaging). The key targets were MMP’s and leukocyte integrins. He has also been involved with e.g. radiation sensitizing, hypoxia, angiogenesis and apoptosis related targeting approaches. He has  also worked with gene therapy radionuclide applications. Now develops PET-tracers for oncology, including early clinical therapy response evaluation.

Besides a few patents prof Kairemo has published more than 200 original articles in peer-reviewed journals. He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) and was President of the 7th International Conference on Radiopharmaceutical Therapy held in November 2012 in Levi in Finnish Lapland.  In 2014, Dr Kairemo hosted ISORBE Symposium and Workshop “Cell Labelling and Cell Therapies” in Helsinki. Now, he is organizing   International Symposium on Radiopharmaceutical Therapy (WARMTH) in November 2018 in Helsinki.

Kamel Hasan, Olfat

To come / À venir

Lafrenière, Nancy

La thérapie doit être adaptée aux besoins spécifiques de la personne pour augmenter l'efficacité et la sécurité de la démarche avec peu ou pas d'effets secondaires.

La dosimétrie est utilisée pour guider la planification du traitement. Soit le radionucléide à utiliser, la quantité de radionucléide donnée, la fréquence des traitements et l'exposition des organes cibles et des tumeurs.

La biodistribution du radionucléide est mesurée sur différents organes à risque ainsi que les tumeurs en traçant des régions d'intérêts reproductibles sur plusieurs images dans le temps.

Le rôle des technologues dans l'acquisition et la génération des images, la rigueur dans les données empiriques est primordial pour le suivi en comparant les données obtenues dans les différents cycles de traitement.

Laidley, David

To come / À venir

eblond, Antoine

To come / À venir

Mawlawi, Osama

To come / À venir

McEwan, Sandy

To come / À venir

Minoshima, Satoshi

To come / À venir

Ouellet, Robert

Physicien médical depuis 30 ans dans divers hôpitaux universitaires du Québec.

Pomerleau-Jobidon, Kim

To come / À venir

Pouliot, Frédéric

Dr. Pouliot is a clinical-scientist and an urologist-oncologist since 2010. He is an associate professor in the Surgery Department of the Faculty of Medicine at Université Laval. He also obtained a Ph.D. in Physiology Endocrinology at Laval University and a post-doc in molecular imaging at UCLA. He has published many articles and reviews on molecular and bioluminescence imaging. His research program has been recognized by different funding organizations such as FRQS Clinical Research Scholar-Junior 1 and 2 and Prostate Cancer Canada-Movember Clinician-Scientist and Rising Star Awards.  Dr Pouliot is also involved in several national and international research clinical trials aiming to improve the prostate cancer management. His center has been the second center in Canada to image prostate cancer patients with Choline PET/CT and he hold positions on the steering committees of three prospective prostate cancer imaging trials and one radioligand therapy trial. His preclinical and clinical research interests include molecular imaging of recurrent and metastatic prostate cancers.

Probst, Stephan

Stephan Probst did a nuclear medicine residency at McGill, followed by a fellowship in PET/CT at NYU. He has been on staff at the Jewish General Hospital since 2010 and he is the Chief of Nuclear Medicine since 2013. His research focuses on PSMA PET/CT and radionuclide therapy of prostate cancer.

Rahmim, Arman

To come / À venir

Rayson, Daniel

Dr. Daniel Rayson is a medical oncologist at the Queen Elizabeth II Health Sciences Centre and Professor of Medicine and Pediatrics at Dalhousie University.  He completed his medical training at Dalhousie, with subsequent fellowship training in Internal Medicine and Hematology/Medical Oncology at the Mayo Clinic in Rochester, Minnesota.  He is past Chair of the Nova Scotia Provincial Breast Cancer Site Team (2000-2009), current Chair of the multidisciplinary Neuroendocrine Tumor Group (2012- ) and past chair of the Clinical Trial Grant Panel Review Committee of the National Cancer Institute of Canada (2006-2009). He has been the Director of the Atlantic Clinical Cancer Research Unit (ACCRU) since 2008, is on the editorial board of the Art of Oncology Section of the Journal of Clinical Oncology and has been section editor of the Cancer Narratives Section of Current Oncology since January 2013. In January 2015, he was appointed Head of the Division of Medical Oncology at the QE II Health Sciences Center.

Ribeiro Monteiro de Godoy, Tássia

Godoy MD is a Nuclear Medicine fellow at University of British Columbia affiliated Teaching Hospitals focusing on scintigraphy and PET-CT imaging, and also focusing on the expected opportunities for the development of new therapeutic agents using radioligand therapy. She completed her Nuclear Medicine training at São Paulo, Brazil, where she also completed a post-graduation in Dermatology and has worked at different private clinics and hospitals in both areas. On completion of her fellowship her aim is to go back to Brazil to work as a Nuclear Medicine specialist with emphasis in the theranostic field and in the hybrid imaging.

Ross, Andrew

Royal College certified nuclear physician and radiologist period.

Has worked in Halifax for over 20 years. Currently division head of nuclear medicine at the QE2 Health Sciences Center. Professor of medicine at Dalhousie University. Current president of CANM and past chair of the Royal College Nuclear Medicine Examination Committee.

Scheiber, Christian

To come / À venir

Soucy, Jean-Paul

Dr. Jean-Paul Soucy Assistant Director, BioImaging, PERFORM Centre, Concordia University and Adjunct Professor, Dpt of Neurology and Neurosurgery, McGill University; Medical Director, PET Unit, Montreal Neurological Institute. He also is a full professor (clinical) in the Department of Radiology, Faculty of Medicine, Université de Montréal.

Dr. Soucy received his Medical Degree (M.D.), and was first in his class, at the Université de Montréal’s School of Medicine (1980). He conducted his residencies from 1980-1984 with the Universite de Montreal and McGill University. Dr. Soucy also received a Masters Degree (M.Sc) in Neuroscience (1993) from the Université de Montréal. He received a C.S.P.Q. Nuclear Medicine (Specialty Certification of the Quebec College of Physicians) in 1984, F.R.C.P.(c) Nuclear Medicne in 1984, a D.E.S. (Specialty Diploma, Nuclear Medicine) from the Université de Montréal, as well as Board Certification, American Board of Nucelar Medicine, in 1984. He was a Post graduate Fellow of the McLaughlin Foundation at service hospitalier Frédéric Joliot, France in 1985.

Dr.Soucy has given over 200 presentations at scientific meetings world-wide, and has been invited to speak at over 70 conferences across Canada, in Brazil and the US. He is or has been a member of a variety of committees including Surveyor for the Royal College of Physicians and Surgeons of Canada since 2000, and Executive Committee Member of the Canadian Association of Nuclear Medicine. He currently is Chair of the Conjoint Committee on Accreditation of the CMA. He is a member of a number of societies including, the Society of Nuclear Medicine, Society for Neuroscience, the Organization for Human Brain Mapping and is a founding member of the Society for Fronto-temporal Dementias.

He has published approximately over 100 abstracts in respected scientific journals, 7 book chapters, and over 50 papers in peer-reviewed journals. He has tutored and supervised medical residents and post-grad students from around the world.  His research interests are in the field of cerebral blood flow quantification and image restoration with SPECT, as well as in vivo acetylcholine imaging in dementia and other neurodegenerative diseases using PET.

Dr Soucy has received many accolades throughout his career, in addition to those for exellence in academic performance, he is the recipient of a prestigious teaching award in two consecutive years, the Prix Esculape – Best teacher in Nuclear Medicine 1991-92, and 1992-93 from hôpital Notre-Dame.

Stevenson, Nigel

Dr. Stevenson obtained his Ph.D. at the University of London, UK in 1983 in Nuclear Physics.  He then worked as a research scientist at TRIUMF, the Canadian national accelerator facility, where he went on to head up the Isotope Production group.  Subsequently, he has held several commercial positions including: V.P. of Isotope Production and Research for Theragenics Corporation, COO of Trace Life Sciences and COO of Clear Vascular, Inc.  Since 2015, Dr. Stevenson has served as the Chief Operating Officer of Serene, LLC – a company that is exploring the treatment of veterinary and human rheumatological conditions with radioactive products.  Dr. Stevenson has organized several isotope conferences over the years including the 3rd International Conference on Isotopes held in Vancouver in September 1999 where he served as the Conference Chairperson.  He has also had various roles in the International Isotope Society including that of the President of the Canadian Chapter and is presently the President of the World Council on Isotopes.

Turcotte, Eric

To come / À venir

Urbain, Jean-Luc

Born in Belgium in the mid 50’s, I earned my Medical Degree at the University of Louvain, Belgium, and then pursued residency training in Internal Medicine and Nuclear Medicine. I subsequently obtained a Ph.D. in Genetics and Molecular Biology at Temple University in Philadelphia. Professor of Imaging, Medicine and Biology for more than two decades I have had the opportunity and privilege to visit hospitals and medical centers and give lecture on all continents. I consider myself as a citizen of the world.

Through my career, I have held leadership and executive positions in Medical Imaging and Medicine in Belgium at the University of Leuven, in Canada at the University of Western Ontario and in the US at Temple University, Fox Chase Cancer Center, The Cleveland Clinic, the VA Administration and now Wake Forest University. I have extensive experience and expertise in committees and boards leadership, in the management of integrated health care systems and patient advocacy groups and at regional, national and international levels of government.

As Secretary of the Belgian Society of Nuclear Medicine in the 90’s I introduced a multilingual and pluralist approach to the operational tasks of the Society. As President of the Canadian Association of Nuclear Medicine (CANM 2006-2011), I have worked closely with national and international medical associations and government health authorities to mitigate major the major health and medical isotopes crises of 2007-2008, analyzed and helped establish medical resources needs, benchmarks and allocation for key medical service areas. I have also served as consultant and advisor for Pharmaceutical, Radio-pharmaceutical and Medical Systems companies.  My current main interests are in Medical Isotopes Production and Supply, Patients’ Education and Advocacy, Personalized Medicine and Theranostics.

As Chief of Nuclear Medicine at Wake Forest University-Baptist Medical Center, Chair of the Scientific Committee of the CANM, Chair of the SNMMI Global Initiative, President Elect of the WFNMB, I am dedicated to work tireless with all stakeholders to improve the management of patients by 1. Securing the supply of Medical Isotopes 2. Developing NM educational tools accessible to the Nuclear Medicine Communities, Patients and Referring Physicians from around the world 3. Promoting the field of Diagnostic and Therapeutic Nuclear Medicine across the globe, particularly in the underserved countries.

Wong, Rebecca

To come / À venir


Powered by Wild Apricot Membership Software